Pharma Analyst

The company has the highest margins within organised diagnostic sector, says market analyst Deven Choksey.

Pharma cos capable of resolving FDA concern in 12-15 months:IIFL

Sharma, however, believes that despite the issues getting compounded by the day, most of the companies have enough capabilities to resolve them within the next 12-15 months.

Poor Dr Reddy's Q4 nos on other income, margin miss: Angel

Shares of pharma company Dr Reddy's Labs jumped as much as 2.2 per cent to hit intraday high of Rs 3,435.80 ahead of its March quarter results which will be declared later in the day.Dr Reddy's reax

USFDA nod will aid Ranbaxy's sentiment, not revenue: Expert

The USFDA today approved Ranbaxy‘s drug called Plendil generic, which is used for hypertension. Ranbaxy was expected to be the authorised generic for this particular drug, but it is already genericised and there are already 6-7 players in this market for this particular drug.

Delhi HC verdict on Januvia boost for Glenmark: Antique

In an interview to CNBC-TV18 pharma analyst, Anmol Ganjoo of Antique Stock Broking said Delhi High court's verdict on Januvia Generic will be a positive for Glenmark Pharma.

Buy Lupin, says Chirag Talati

Buy Lupin, says Chirag Talati, Pharma Analyst, Espirito Santo Securities.

Elara's take on top pharma stocks: Ranbaxy, DRL, Cipla

Surajit Pal, Pharma Analyst at Elara Capital, in an interview with CNBC-TV18's Latha Venkatesh and Sonia Shenoy, spoke about his reading of the pharma sector and his outlook on a few stocks.